News stories about Biodel (NASDAQ:ALBO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Biodel earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.4642783860092 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Biodel (NASDAQ ALBO) opened at 22.09 on Tuesday. Biodel has a 12-month low of $12.30 and a 12-month high of $37.69. The stock’s market cap is $196.20 million. The stock’s 50 day moving average is $23.53 and its 200-day moving average is $22.43.
Biodel (NASDAQ:ALBO) last released its quarterly earnings results on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02). Equities analysts anticipate that Biodel will post ($3.64) EPS for the current fiscal year.
ALBO has been the subject of a number of research analyst reports. Wedbush initiated coverage on shares of Biodel in a research report on Friday, June 30th. They set an “outperform” rating for the company. Needham & Company LLC initiated coverage on shares of Biodel in a research report on Tuesday, July 18th. They set a “buy” rating and a $35.00 price objective for the company. Zacks Investment Research cut shares of Biodel from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, Cowen and Company began coverage on shares of Biodel in a report on Wednesday, August 16th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $40.33.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://ledgergazette.com/2017/09/26/biodel-albo-earning-somewhat-positive-press-coverage-analysis-shows.html.
Biodel Company Profile
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.